Patient information
| Characteristic . | Variable . | Genomic sample set (N = 370) . | Clinical sample set (N = 343) . | ||
|---|---|---|---|---|---|
| n . | % of evaluable patients . | n . | % of evaluable patients . | ||
| Sex | |||||
| Male | 202 | 56.1 | 192 | 56 | |
| Female | 158 | 43.9 | 151 | 44 | |
| Age, y | |||||
| Median | 60 | 60 | |||
| <40 | 25 | 7.2 | 25 | 7.6 | |
| 40–60 | 154 | 44.4 | 147 | 44.5 | |
| 60–80 | 154 | 44.4 | 144 | 43.6 | |
| ≥80 | 14 | 4 | 14 | 4.2 | |
| Lymphoma subtype | |||||
| FL | 323 | 87.3 | 296 | 86.3 | |
| t-FL | 47 | 12.7 | 47 | 13.7 | |
| FL grade | |||||
| Grade 1-2 | 247 | 82.6 | 235 | 83 | |
| Grade 3A | 52 | 17.4 | 48 | 17 | |
| Sequenced sample | |||||
| Diagnostic | 253 | 76.7 | 253 | 76.7 | |
| Relapse #1 | 36 | 10.9 | 36 | 10.9 | |
| Relapse #2+ | 41 | 12.4 | 41 | 12.4 | |
| FLIPI: nodal involvement | |||||
| 0-4 regions | 172 | 71.7 | 156 | 69.6 | |
| ≥5 regions | 68 | 28.3 | 68 | 30.4 | |
| FLIPI: LDH | |||||
| Normal | 231 | 83.1 | 218 | 82.9 | |
| Elevated | 47 | 16.9 | 45 | 17.1 | |
| FLIPI: age (y) | |||||
| <60 | 144 | 48 | 139 | 49.1 | |
| ≥60 | 156 | 52 | 144 | 50.9 | |
| FLIPI: stage | |||||
| Early (I-II) | 63 | 21.3 | 59 | 21.1 | |
| Advanced (III-IV) | 233 | 78.7 | 221 | 78.9 | |
| FLIPI: hemoglobin | |||||
| <12 g/dL | 32 | 13.5 | 29 | 13.2 | |
| ≥12 g/dL | 205 | 86.5 | 191 | 86.8 | |
| FLIPI: risk strata | |||||
| Low (0-1) | 101 | 33.9 | 97 | 34.4 | |
| Intermediate (2) | 106 | 35.6 | 100 | 35.5 | |
| High (3-5) | 91 | 30.5 | 85 | 30.1 | |
| Treatment history | |||||
| (any line of treatment) | Initial W&W | – | – | 48 | 14.5 |
| Anti-CD20 mAb | – | – | 282 | 85.2 | |
| CHOP/CVP | – | – | 168 | 50.8 | |
| Bendamustine | – | – | 56 | 16.9 | |
| Lenalidomide | – | – | 31 | 9.4 | |
| Autologous SCT | – | – | 25 | 7.6 | |
| Characteristic . | Variable . | Genomic sample set (N = 370) . | Clinical sample set (N = 343) . | ||
|---|---|---|---|---|---|
| n . | % of evaluable patients . | n . | % of evaluable patients . | ||
| Sex | |||||
| Male | 202 | 56.1 | 192 | 56 | |
| Female | 158 | 43.9 | 151 | 44 | |
| Age, y | |||||
| Median | 60 | 60 | |||
| <40 | 25 | 7.2 | 25 | 7.6 | |
| 40–60 | 154 | 44.4 | 147 | 44.5 | |
| 60–80 | 154 | 44.4 | 144 | 43.6 | |
| ≥80 | 14 | 4 | 14 | 4.2 | |
| Lymphoma subtype | |||||
| FL | 323 | 87.3 | 296 | 86.3 | |
| t-FL | 47 | 12.7 | 47 | 13.7 | |
| FL grade | |||||
| Grade 1-2 | 247 | 82.6 | 235 | 83 | |
| Grade 3A | 52 | 17.4 | 48 | 17 | |
| Sequenced sample | |||||
| Diagnostic | 253 | 76.7 | 253 | 76.7 | |
| Relapse #1 | 36 | 10.9 | 36 | 10.9 | |
| Relapse #2+ | 41 | 12.4 | 41 | 12.4 | |
| FLIPI: nodal involvement | |||||
| 0-4 regions | 172 | 71.7 | 156 | 69.6 | |
| ≥5 regions | 68 | 28.3 | 68 | 30.4 | |
| FLIPI: LDH | |||||
| Normal | 231 | 83.1 | 218 | 82.9 | |
| Elevated | 47 | 16.9 | 45 | 17.1 | |
| FLIPI: age (y) | |||||
| <60 | 144 | 48 | 139 | 49.1 | |
| ≥60 | 156 | 52 | 144 | 50.9 | |
| FLIPI: stage | |||||
| Early (I-II) | 63 | 21.3 | 59 | 21.1 | |
| Advanced (III-IV) | 233 | 78.7 | 221 | 78.9 | |
| FLIPI: hemoglobin | |||||
| <12 g/dL | 32 | 13.5 | 29 | 13.2 | |
| ≥12 g/dL | 205 | 86.5 | 191 | 86.8 | |
| FLIPI: risk strata | |||||
| Low (0-1) | 101 | 33.9 | 97 | 34.4 | |
| Intermediate (2) | 106 | 35.6 | 100 | 35.5 | |
| High (3-5) | 91 | 30.5 | 85 | 30.1 | |
| Treatment history | |||||
| (any line of treatment) | Initial W&W | – | – | 48 | 14.5 |
| Anti-CD20 mAb | – | – | 282 | 85.2 | |
| CHOP/CVP | – | – | 168 | 50.8 | |
| Bendamustine | – | – | 56 | 16.9 | |
| Lenalidomide | – | – | 31 | 9.4 | |
| Autologous SCT | – | – | 25 | 7.6 | |
CHOP, cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; LDH, lactate dehydrogenase; mAb, monoclonal antibody; SCT, stem cell transplantation; W&W, watch-and-wait.